$4.68
-0.13 (-2.60%)
Open$4.79
Previous Close$4.80
Day High$5.07
Day Low$4.52
52W High$20.00
52W Low$3.29
Volume—
Avg Volume24.2K
Market Cap15.45M
P/E Ratio—
EPS$-11.32
SectorBiotechnology
Analyst Ratings
Buy
9 analysts
Price Target
+677.1% upside
Current
$4.68
$4.68
Target
$36.33
$36.33
$21.56
$36.33 avg
$42.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.14M | 4.29M | 4.24M |
| Net Income | -270,468 | -254,054 | -270,426 |
| Profit Margin | -6.5% | -5.9% | -6.4% |
| EBITDA | -483,031 | -431,767 | -494,923 |
| Free Cash Flow | -204,723 | -222,413 | -294,472 |
| Rev Growth | -4.9% | +3.8% | -2.6% |
| Debt/Equity | 0.13 | 0.14 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |